Biomarin Pharmaceutical Inc. (BMRN)
Compared to Estimates, BioMarin (BMRN) Q3 Earnings: A Look at Key Metrics
The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BioMarin: Valuation, Growth, And The Pipeline May Outweigh TransCon Competition And Regulatory Risks
BioMarin has both a solid revenue portfolio of several products and a promising pipeline. The market's main concern has been TransCon competition; however, the combination of Voxzogo and BMN 333 could effectively fight back. Even if the U.S. government were to regulate prices, it would only affect a small portion of the company, since 64% of its sales originate outside the US.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BioMarin Pharmaceutical Inc. (BMRN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 11:30 AM EDT Company Participants Alexander Hardy - President, CEO & Director Brian Mueller - Executive VP of Finance, CFO & Principal Accounting Officer Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morning, everyone, and welcome to this good morning. Welcome to Morgan Stanley Global Healthcare Conference.
BioMarin Pharmaceutical Inc. (BMRN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:45 AM EDT Company Participants Gregory Friberg - Executive VP and Chief Research & Development Officer Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst All right. Thank you very much for joining us today.
BioMarin Pharmaceutical Inc. (BMRN) Presents At Cantor Global Healthcare Conference 2025 Transcript
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Cantor Global Healthcare Conference 2025 September 3, 2025 8:00 AM EDT Company Participants Gregory Friberg - Executive VP and Chief Research & Development Officer Conference Call Participants Olivia Brayer - Cantor Fitzgerald & Co., Research Division Presentation Olivia Brayer Research Analyst Okay. Great. Hey, good morning, everyone.
BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View
BMRN's Q2 earnings surge 50% on strong Voxzogo and enzyme therapy sales, prompting a raised 2025 revenue and EPS outlook.
BioMarin Pharmaceutical Inc. (BMRN) Q2 2025 Earnings Call Transcript
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Alexander Hardy - President, CEO & Director Brian R. Mueller - Executive VP of Finance & CFO Cristin Hubbard - Executive VP & Chief Commercial Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Traci McCarty - Group Vice President Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Alexandria Janet Hammond - Wolfe Research, LLC Allison Marie Bratzel - Piper Sandler & Co., Research Division Cory William Kasimov - Evercore ISI Institutional Equities, Research Division Ellen Horste - TD Cowen, Research Division Huidong Wang - Barclays Bank PLC, Research Division Jasmine Alexandra Fels - UBS Investment Bank, Research Division Jason Matthew Gerberry - BofA Securities, Research Division Konstantinos Biliouris - BMO Capital Markets Equity Research Olivia Simone Brayer - Cantor Fitzgerald & Co., Research Division Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Sean M.
